Wednesday, Spectranetics Corp. (SPNC) announced publication of CLiRpath Excimer Laser System to Enlarge Lumen Openings or CELLO study, that evaluated the effectiveness of excimer laser ablation with the Turbo-Booster, for patients with Peripheral Artery Disease or PAD, in the December issue of the Journal of Endovascular Therapy. PAD is a widespread condition affecting about eight million Americans, with most incidences occurring above the knee. Left untreated, PAD can lead to ulcers that do not heal, gangrene and even amputation.
The company revealed that the FDA-cleared laser treatment met its primary endpoint by reducing, on average, the percent diameter stenosis to 42.5% from 77.3% immediately post Turbo-Booster use, exceeding the goal of a 20% difference. In addition, the Turbo-Booster had a low number of repeat vascular interventions, while safely improving a range of clinical and functional status assessments, Spectranetics noted.
Rajesh Dave, principal investigator of the CELLO trial and chairman, Endovascular Medicine, Pinnacle Health Heart and Vascular Institute said, "Preventing the millions of leg amputations caused by PAD represents an urgent medical imperative. The best way to preserve limbs is by creating larger blood vessel cavities, also known as the lumen. This study demonstrated the Turbo-Booster's ability to produce larger lumens than what was previously achieved by excimer laser catheters alone. This may help reduce the need for aggressive adjunctive therapy, like stenting."
SPAC is being traded at $6.81 up $ 0.11 or 1.64% on he NASDAQ.
For comments and feedback: editorial@rttnews.com